Lanham O'Dell & Company’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $304K | Sell |
14,000
-1,000
| -7% | -$21.7K | 0.13% | 21 |
|
|
2025
Q1 | $364K | Hold |
15,000
| – | – | 0.21% | 14 |
|
|
2024
Q4 | $313K | Sell |
15,000
-2,000
| -12% | -$41.7K | 0.17% | 16 |
|
|
2024
Q3 | $338K | Sell |
17,000
-3,000
| -15% | -$59.6K | 0.19% | 16 |
|
|
2024
Q2 | $310K | Hold |
20,000
| – | – | 0.17% | 19 |
|
|
2024
Q1 | $319K | Sell |
20,000
-645
| -3% | -$10.3K | 0.16% | 22 |
|
|
2023
Q4 | $347K | Sell |
20,645
-355
| -2% | -$5.97K | 0.24% | 21 |
|
|
2023
Q3 | $245K | Hold |
21,000
| – | – | 0.2% | 15 |
|
|
2023
Q2 | $282K | Hold |
21,000
| – | – | 0.26% | 13 |
|
|
2023
Q1 | $348K | Buy |
21,000
+1,000
| +5% | +$16.6K | 0.38% | 13 |
|
|
2022
Q4 | $372K | Sell |
20,000
-145
| -0.7% | -$2.7K | 0.81% | 12 |
|
|
2022
Q3 | $258K | Buy |
+20,145
| New | +$258K | 0.92% | 24 |
|
|
2022
Q2 | – | Sell |
-26,500
| Closed | -$220K | – | 20 |
|
|
2022
Q1 | $220K | Sell |
26,500
-23,500
| -47% | -$195K | 0.17% | 17 |
|
|
2021
Q4 | $339K | Buy |
+50,000
| New | +$339K | 0.27% | 14 |
|